Posted by Michael Wonder on 06 Sep 2025
Accrufer assigned priority review in the US by FDA in children with iron deficiency anaemia
4 September 2025 - Pending successful review, approval in the US is anticipated in 2026.
Shield Therapeutics announces that the US FDA has accepted Accrufer/Ferracru (ferric maltol) as a clinical supplement and assigned Priority Review to extend the indication for Accrufer/Ferracru to include adolescents aged 10 years and above.
